ReviewCurrent rheumatology reports2011
Treatment of mild, moderate, and severe lupus erythematosus: focus on new therapies.
Review in Current rheumatology reports, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 26 citations in OpenAlex.
- Impaired Cytokine Responses to Epstein-Barr Virus Antigens in Systemic Lupus Erythematosus Patients.Journal of immunology research · 2016Article
- Quality of life and acquired organ damage are intimately related to activity limitations in patients with systemic lupus erythematosus.BMC musculoskeletal disorders · 2015Article
- Article
- Positive correlation of STAT1 and miR-146a with anemia in patients with systemic lupus erythematosus.Journal of clinical immunology · 2014Article
- Reduced levels of CCL2 and CXCL10 in systemic lupus erythematosus patients under treatment with prednisone, mycophenolate mofetil, or hydroxychloroquine, except in a high STAT1 subset.Arthritis research & therapy · 2014Article
- Reduced response to Epstein-Barr virus antigens by T-cells in systemic lupus erythematosus patients.Lupus science & medicine · 2014Article
- Genetic variants synthesize to produce paneth cell phenotypes that define subtypes of Crohn's disease.Gastroenterology · 2014Article
- Cellular and urinary microRNA alterations in NZB/W mice with hydroxychloroquine or prednisone treatment.International immunopharmacology · 2013Article
- Clinical implications of shared genetics and pathogenesis in autoimmune diseases.Nature reviews. Endocrinology · 2013Review
- Epstein-Barr virus and systemic lupus erythematosus.Clinical & developmental immunology · 2012Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Despite large-scale efforts devoted to the conduct of clinical trials in systemic lupus erythematosus (SLE), no new therapy has been approved for treatment of this disease in more than 50 years. Increased understanding of the immunologic mechanisms underlying SLE has led to the development of a variety of biologic agents that target specific aspects of the adaptive and innate arms of the immune system, including B cells, T cells, dendritic cells, and various cytokines. One of these agents, belimumab, was the subject of two positive phase 3 trials in nonrenal lupus that have given us hope that a new therapy for SLE may be finally within our grasp. In addition to these newer therapies, recent studies of standard-of-care medications such as mycophenolate mofetil and hydroxychloroquine have better defined the efficacy and safety of these agents for the treatment of lupus nephritis and nonrenal lupus. This article provides a discussion of several novel biologic agents at different stages of development for the treatment of SLE, as well as an analysis of newer data on agents that have been used in the treatment of SLE for many years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.